Abstract
BackgroundChimeric antigen receptor (CAR) T cell therapy has shown outstanding benefit in hematological malignancies with three autologous CAR-T therapies commercially available and several in clinical development. The use of autologous...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
